Photo: Chris Potter - www.stockmonkeys.comOn 27 August 2020, the Dutch Ministry of Economic Affairs responded in a letter to the Parliament to the SOMO report ‘Overpriced: drugs developed with Dutch Public Funding‘.
On our Dutch website you find a reaction of SOMO and Wemos on this.
As some Development Assistance Committee (DAC) donors are considering using their Official Development Aid (ODA) budgets to cover expenditures related to Covid-19 vaccines, the work of the DAC is critical to ensure that ODA eligibility…
Vaccine manufacturer Moderna is employing tax avoidance structures to shift its profits to Switzerland and the US state of Delaware, research by SOMO in cooperation with Wemos. The European Union ordered $10.3 billion worth of…
Conditions attached to Dutch government investments in corona vaccines and medication to guarantee affordability and accessibility are are insufficient at best and, at worst, counterproductive. Vaccine manufacturing companies are able to negotiate conditions into the…
SOMO is co-organising two debates (in Dutch) in the run-up to the Dutch elections on 17 March. Het Grote Buitenlanddebat – 24 February During the “Grote Buitenlanddebat”, candidate MPs will debate the role of the…
In a joint letter, SOMO together with 53 civil society organisations are calling upon the Dutch government to ensure that pharmaceutical companies share their knowledge of vaccine development with other companies in an existing pool…
A group of 39 civil society organisations, including SOMO is calling on the European Commission and EU national governments to ensure a maximum degree of transparency in the EU’s exchanges, negotiations and deals with pharmaceutical…
More than hundred civil society organizations, including SOMO, signed this open letter to the European Parliament and national parliaments that calls for support for the proposal that ensures equal and affordable access for all people…
This infographic shows the tax avoidance structure of biotech company Qiagen, a major producer of corona test kits.